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The phosphoinositide 3-kinase (PI3K)/mammalian target of
rapamycin (mTOR) pathway is very frequently activated in human
cancer by a variety of genetic and epigenetic events. This path-
way is thought to contribute to many of the hallmarks of cancer
and a large array of agents targeting its key components are cur-
rently undergoing clinical testing in cancer patients. In addition to
rapamycin analogs (“rapalogs”), which are approved for the treat-
ment of multiple cancers, PI3K inhibitors are likely to be soon
approved for B-cell malignancies (1, 2).
In this research topic, we have assembled a collection of arti-
cles describing recent key aspects of the role of the PI3K/mTOR
pathway in cancer and the development of targeted therapies.
Martini et al. review the role of the different classes of PI3K
isoforms as targets in oncology (3). Tzenaki and Papakonstanti
focus on the role of the PI3K isoform p110δ in cancer (4). The role
of the PI3K/mTOR pathway in cell cycle progression and metab-
olism is discussed by Vadlakonda and colleagues (5–7). Pardo and
Seckl present an overview of S6K2, the p70 ribosomal S6 kinase
homolog (8).
Porta and colleagues present an up to date overview of the
development of selective inhibitors of Akt, mTOR, and PI3K with
a focus on the latest clinical trials (9). Weigelt and Downward
review the genetic determinants of response to these targeted
agents (10). Fox et al. discuss the potential of co-targeting PI3K
and the estrogen receptor (ER) in breast cancer (11).
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